New viral gene-delivery tools aimed at fat tissue
Next generation of AAV vector targeting adipose tissue
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-11323002
This project develops engineered AAV viral capsids and expression designs to deliver genes specifically into fat (adipose) tissue with less activity in the liver.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-11323002 on ClinicalTrials.gov |
What this research studies
Researchers are building on an engineered AAV capsid called Rec2 that reaches fat cells well but also ends up in the liver. They will create next-generation capsids and improve genetic 'dual-cassette' designs to limit off-target activity in the liver and to overcome cargo-size and RNA-based transgene limitations. The team will test how well these vectors target adipose, how they spread through the body, and whether they reduce liver exposure using laboratory and preclinical models. The goal is safer, more selective gene-delivery tools that could enable future therapies for adipose-related conditions.
Who could benefit from this research
Good fit: Ideal future candidates would be people with genetic or metabolic conditions tied to adipose dysfunction who might benefit from targeted gene delivery to fat tissue.
Not a fit: People whose conditions do not involve adipose tissue or who are not eligible for gene therapy would not be expected to benefit from this work in the near term.
Why it matters
Potential benefit: If successful, this work could enable gene therapies that correct or improve disorders linked to adipose tissue while lowering the risk of liver-related side effects.
How similar studies have performed: AAV vectors have a strong clinical track record in other organs, and preclinical work with Rec2 shows promising adipose targeting, but adipose-directed AAV therapy remains largely unproven in humans.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CAO, LEI — OHIO STATE UNIVERSITY
- Study coordinator: CAO, LEI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.